Pediatric Endocrinology
Learning Objectives
By the end of this page, you should be able to:
- Describe the pathophysiology, presentation, and management of type 1 diabetes mellitus in children.
- Differentiate growth hormone deficiency from other causes of short stature and outline the diagnostic workup.
- Explain why newborn screening for congenital hypothyroidism is time-critical and describe its treatment.
- Interpret basic thyroid and growth hormone axis physiology (hypothalamus-pituitary-target organ).
- Recognize diabetic ketoacidosis as a pediatric emergency and list its key management steps.
- Identify common exam pitfalls in pediatric endocrine disorders.
Quick Answer
Pediatric endocrinology deals with hormone-driven growth and metabolic problems unique to children — most importantly type 1 diabetes mellitus, growth hormone deficiency, and congenital hypothyroidism. It matters because these conditions are diagnosed and treated differently in children than adults: growth and pubertal development are ongoing processes that hormones drive, so a missed or delayed diagnosis (like untreated congenital hypothyroidism) causes permanent harm — irreversible intellectual disability — that adult endocrinology rarely has to worry about. Early recognition through growth charts, newborn screening, and a high index of suspicion is the core skill tested in exams and needed in practice.
Type 1 Diabetes Mellitus in Children
What it is: Autoimmune destruction of pancreatic beta cells leads to absolute insulin deficiency. It is the most common endocrine emergency in pediatrics and the most common form of diabetes in children, though type 2 diabetes is rising with childhood obesity.
How it presents: Classic triad of polyuria, polydipsia, and weight loss, often triggered or unmasked by a viral illness. Many children first present in diabetic ketoacidosis (DKA) — vomiting, abdominal pain, Kussmaul breathing, fruity (acetone) breath, and altered consciousness. Because children cannot always articulate symptoms, DKA at diagnosis is common and is a genuine pediatric emergency.
Diagnosis: Random plasma glucose ≥200 mg/dL with symptoms, or fasting glucose ≥126 mg/dL, or HbA1c ≥6.5%. Autoantibodies (GAD65, islet cell, insulin) support the type 1 diagnosis and distinguish it from type 2 or MODY.
Management:
- Acute DKA: IV fluids, then insulin infusion (never bolus insulin first — this precipitates cerebral edema), careful potassium replacement, and slow correction of osmolality.
- Chronic: basal-bolus insulin regimens or continuous subcutaneous insulin infusion (insulin pump), carbohydrate counting, and continuous glucose monitoring.
- Goal: HbA1c <7% while avoiding hypoglycemia, since tight control without hypoglycemia awareness is dangerous in young children.
Why it matters: Poor glycemic control in childhood predicts microvascular and macrovascular complications decades earlier than in adults who develop diabetes later in life, so early, consistent control changes lifelong outcomes.
Growth Hormone Disorders
What it is: Growth hormone (GH), secreted by the anterior pituitary under hypothalamic GHRH stimulation, drives linear growth largely through hepatic IGF-1 production. GH deficiency (GHD) — from pituitary tumors, cranial irradiation, genetic mutations, or idiopathic causes — leads to short stature with a normal birth length that progressively falls off the growth curve.
How it's worked up: Short stature is defined as height below the 3rd percentile (or >2 SD below the mean) for age and sex. The workup separates GHD from far more common causes: familial short stature, constitutional delay of growth and puberty, chronic disease, and syndromes (Turner, skeletal dysplasias).
Key tools: growth curve trend (crossing percentiles is more worrying than being consistently short), bone age X-ray (delayed bone age suggests GHD or constitutional delay; bone age matching chronological age suggests familial short stature), IGF-1/IGFBP-3 screening, and GH provocative (stimulation) testing — since random GH levels are pulsatile and uninformative, two abnormal stimulation tests (e.g., with clonidine, arginine, or insulin) are required to confirm GHD.
Treatment: Daily subcutaneous recombinant human GH (rhGH) injections, continued until growth plates fuse or growth velocity plateaus. Response is monitored by height velocity and IGF-1 levels; earlier treatment gives better final adult height.
Common misunderstanding: Short stature does not automatically mean GH deficiency — most short children have familial short stature or constitutional delay, both of which are normal variants, not disease.
Congenital Hypothyroidism
What it is: Thyroid hormone deficiency present at birth, most often from thyroid dysgenesis (agenesis, ectopic, or hypoplastic gland) or, less commonly, dyshormonogenesis (an enzyme defect in hormone synthesis) or maternal factors.
Why it's time-critical: Thyroid hormone is essential for brain myelination and neuronal development in the first weeks to months of life. Unlike hypothyroidism acquired later in childhood or adulthood, untreated congenital hypothyroidism causes irreversible intellectual disability ("cretinism") — this is precisely why universal newborn screening (heel-prick TSH, usually on day 2-5 of life) exists in virtually every country.
Presentation (often subtle or absent at birth): Prolonged jaundice, hypotonia, macroglossia, umbilical hernia, constipation, hoarse cry, large fontanelles, and lethargy/poor feeding — but many infants look entirely normal, which is exactly why screening (not clinical suspicion) is relied upon.
Diagnosis: Elevated TSH with low free T4 on newborn screen, confirmed with venous thyroid function tests. Thyroid ultrasound or scintigraphy can identify the underlying cause but should not delay treatment.
Treatment: Oral levothyroxine started immediately (ideally within the first 2 weeks of life), dosed to keep free T4 in the upper half of the normal range and TSH normalized, with regular monitoring through infancy and childhood as the dose is adjusted for growth.
Outcome: With prompt treatment started early, cognitive outcomes are normal; delay of even a few weeks measurably lowers IQ outcomes — this is the single fact examiners test most often.
Key Terms
| Term | Meaning |
|---|---|
| ACTH | Adrenocorticotropic hormone; pituitary hormone stimulating adrenal cortisol production |
| Bone age | Radiographic estimate of skeletal maturity, compared with chronological age to assess growth disorders |
| DKA (Diabetic Ketoacidosis) | Life-threatening complication of insulin deficiency: hyperglycemia, ketosis, and metabolic acidosis |
| GH (Growth Hormone) | Pituitary hormone that stimulates linear growth, mainly via hepatic IGF-1 |
| IGF-1 | Insulin-like growth factor-1; the main mediator of GH's growth-promoting effects, used as a GH-axis screening test |
| Newborn screening | Mandatory heel-prick testing shortly after birth that detects congenital hypothyroidism, among other conditions, before symptoms appear |
| Provocative (stimulation) testing | Pharmacologic tests (e.g., clonidine, insulin, arginine) used to unmask GH deficiency because random GH levels are unreliable |
| TSH | Thyroid-stimulating hormone; elevated in primary hypothyroidism, including the congenital form |
| Type 1 diabetes mellitus | Autoimmune beta-cell destruction causing absolute insulin deficiency, typically presenting in childhood |
Common Mistakes
| Misconception | Why It's Wrong | Correct Understanding |
|---|---|---|
| "A single low GH blood level proves growth hormone deficiency." | GH is secreted in pulses; a random level can be low even in a healthy child. | Diagnosis requires two abnormal GH provocative (stimulation) tests plus supporting growth/IGF-1 data. |
| "A newborn with congenital hypothyroidism will look visibly sick, so clinical exam is enough to catch it." | Most affected newborns appear clinically normal in the first days of life; signs like macroglossia and hypotonia develop later. | Universal biochemical newborn screening (TSH/T4), not physical exam, is what actually catches the condition early enough to prevent brain injury. |
| "In DKA, giving an insulin bolus first speeds up recovery." | An initial insulin bolus in children risks rapid osmotic shifts that can precipitate life-threatening cerebral edema. | Start IV fluid resuscitation first, then begin an insulin infusion (no bolus), correcting glucose and electrolytes gradually. |
Comparison and Connections
| Feature | Growth Hormone Deficiency | Congenital Hypothyroidism | Type 1 Diabetes Mellitus |
|---|---|---|---|
| Underlying defect | Deficient GH secretion or action | Deficient thyroid hormone from birth | Autoimmune beta-cell destruction |
| Key screening tool | Growth curve + bone age | Newborn heel-prick TSH | Symptoms + random/fasting glucose |
| Urgency of treatment | Important but not emergent | Extremely time-critical (brain development) | Can present as an acute emergency (DKA) |
| Mainstay treatment | Daily rhGH injections | Daily levothyroxine | Insulin (basal-bolus or pump) |
| Consequence if missed | Reduced final adult height | Irreversible intellectual disability | Death from DKA if unrecognized |
Practice Questions
Recall
- What are the two biochemical newborn screening findings that define congenital hypothyroidism? Answer guidance: elevated TSH with low free T4.
- Name three classic symptoms of new-onset type 1 diabetes in a child. Answer guidance: polyuria, polydipsia, weight loss (also polyphagia, fatigue).
Understanding
- Why does congenital hypothyroidism require urgent treatment while growth hormone deficiency does not carry the same time pressure? Answer guidance: thyroid hormone is essential for early brain myelination — a window that closes within months — while GH deficiency mainly affects final height, which can still be improved even if treatment starts somewhat later.
- Why are two abnormal GH stimulation tests required instead of one blood test? Answer guidance: GH is secreted in pulses, so a single random value is unreliable; two independent provocative tests reduce false positives.
Application
- A 6-year-old boy has fallen from the 50th to the 10th height percentile over 18 months, with bone age reading as 4 years. What is the most useful next step? Answer guidance: screen IGF-1/IGFBP-3 and thyroid function, then proceed to GH stimulation testing if screening suggests GH axis dysfunction.
- A previously well 7-year-old presents with vomiting, deep rapid breathing, and a fruity odor on his breath after a cold. What is the immediate first management step? Answer guidance: confirm DKA (glucose, ketones, blood gas), then start IV fluid resuscitation before initiating an insulin infusion — no insulin bolus.
Analysis
- Compare why a delay in diagnosis is far more damaging in congenital hypothyroidism than in growth hormone deficiency, even though both cause growth impairment if untreated. Answer guidance: GHD primarily affects skeletal growth, which is at least partially reversible with later treatment; hypothyroidism in infancy affects neurodevelopment during a critical, non-reversible window, so delay causes permanent cognitive harm rather than just a height deficit.
- A short child has bone age equal to chronological age and a strong family history of short adult height. Contrast this with a short child whose bone age is markedly delayed. What does each pattern suggest, and why? Answer guidance: bone age matching chronological age with a short family history suggests familial short stature (a normal variant, growth plates mature normally); markedly delayed bone age suggests either constitutional delay of growth and puberty (will catch up) or a pathological process like GH deficiency or hypothyroidism (bone maturation is hormone-dependent and stalls without treatment) — further testing (IGF-1, thyroid function, GH stimulation) is needed to distinguish these.
FAQ
1. Is type 1 diabetes in children curable? No. It requires lifelong insulin replacement; there is no cure, though pump technology and closed-loop ("artificial pancreas") systems make control easier.
2. Can a child with growth hormone deficiency reach a normal adult height? Often yes, especially if rhGH therapy starts early, before growth plates near fusion — the earlier treatment begins, the better the final height outcome.
3. If a baby with congenital hypothyroidism looks completely normal, can screening still be trusted? Yes — that's the whole point of screening. Most affected newborns look normal at birth; the biochemical test detects the deficiency before physical signs (which take weeks) or brain injury develops.
4. Does type 1 diabetes always start with DKA? No, but it is common, especially in younger children or when symptoms are missed; recognizing early polyuria/polydipsia can prevent a DKA presentation.
5. Are all short children endocrine patients? No — most short stature is familial or constitutional, both normal variants. Endocrine causes like GH deficiency or hypothyroidism are a minority but must be actively screened for, especially when growth velocity is abnormal.
Quick Revision
- Type 1 DM: autoimmune beta-cell loss to absolute insulin deficiency; classic triad = polyuria, polydipsia, weight loss.
- DKA is a medical emergency: IV fluids first, then insulin infusion (never insulin bolus first — risk of cerebral edema).
- GH acts mainly through hepatic IGF-1; random GH levels are unreliable due to pulsatile secretion.
- GH deficiency diagnosis needs two abnormal GH provocative/stimulation tests, not one.
- Bone age matching chronological age + family history → think familial short stature (normal variant).
- Delayed bone age → think GH deficiency, hypothyroidism, or constitutional delay (workup needed).
- Congenital hypothyroidism is usually caused by thyroid dysgenesis; most affected infants look normal at birth.
- Universal newborn heel-prick screening (TSH/T4) — not physical exam — catches congenital hypothyroidism early.
- Congenital hypothyroidism treatment (levothyroxine) must start within the first weeks of life to prevent irreversible intellectual disability.
- rhGH is given as daily subcutaneous injections until growth plates fuse.
- Key hormone axis: hypothalamus (GHRH/TRH) → pituitary (GH/TSH) → target organ (liver/IGF-1, thyroid/T4).
- HbA1c target in pediatric type 1 diabetes is generally <7%, balanced against avoiding hypoglycemia.
Related Topics
Prerequisites
- Basic endocrine physiology: hypothalamic-pituitary axis, negative feedback loops
- Normal growth and pubertal milestones in children
Related Topics
- Adrenal disorders in children (congenital adrenal hyperplasia, adrenal insufficiency)
- Disorders of sexual differentiation and puberty (precocious/delayed puberty)
- Fluid and electrolyte management in pediatrics (relevant to DKA management)
Next Topics
- Pediatric adrenal and pubertal disorders
- Inherited metabolic disorders in children
- Adult endocrinology transition-of-care principles